A regulation in the US which attempts to give seriously ill patients access to new developmental drugs as early as possible. These drugs are generally made available during phase III studies before general marketing begins.
Search and browse hundreds of industry specific terms and phrases or suggest your own terms and definitions.
A regulation in the US which attempts to give seriously ill patients access to new developmental drugs as early as possible. These drugs are generally made available during phase III studies before general marketing begins.
Related terms
In-house newspaper/magazine, Decision flow diagram, Marketing myopia, Prior approval, Inclusion/exclusion criteria, Side-effects, Health technology assessment/appraisal (HTA), “P” Medicine, Market growth rate, Omnibus survey, Publics, Market entry barrier, List building, Substantiation, Logo,